Full Disclosure Policy Affecting CE Activities: As a sponsor accredited by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:
PROGRAM DIRECTOR
Jacquelyn L. Bainbridge, PharmD, FCCP Associate Professor Department of Clinical Pharmacy University of Colorado at Denver and Health Sciences Center Denver, Colorado • Dr Bainbridge reports receiving grants/research support from Biogen Idec; and receiving honoraria from Teva Neuroscience and Serono.
PARTICIPATING FACULTY
Jeffrey L. Bennett, MD, PhD Associate Professor of Neurology and Ophthalmology University of Colorado Health Sciences Center Denver, Colorado • Dr Bennett reports receiving grants/research support from EMD Serono and Pfizer Inc; serving as a consultant for Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience; and receiving honoraria from EMD Serono and Pfizer Inc.
Richard L. Cook, PharmD Adjunct Clinical Assistant Professor Manager, Clinical and Quality Programs University of Michigan College of Pharmacy Ann Arbor, Michigan • Dr Cook reports receiving honoraria from Berlex, Biogen Idec, and Teva Neuroscience.
Ellen Whipple Guthrie, PharmD Clinical Assistant Professor University of Georgia College of Pharmacy Athens, Georgia • Dr Guthrie reports serving as a consultant for the Multiple Sclerosis Foundation; and being a stock shareholder of Teva Pharmaceuticals.
Amy C. Rauchway, DO Diplomate of the American Board of Psychiatry and Neurology Assistant Professor Department of Neurology Saint Louis University St. Louis, Missouri • Dr Rauchway reports receiving grants/research support from EMD Serono and Pfizer Inc; serving as a consultant for Bayer Healthcare, EMD Serono, and Teva Neuroscience; and receiving honoraria from Teva Neuroscience.
Melody Ryan, PharmD, MPH, BCPS, CGP Associate Professor Department of Pharmacy Practice and Science University of Kentucky College of Pharmacy Department of Neurology University of Kentucky College of Medicine Clinical Pharmacy Specialist (WOC) Lexington VA Medical Center Lexington, Kentucky • Dr Ryan reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Kim Tallian, PharmD, BCPP, FASHP, FCSHP Pharmacy Psychiatry Specialist University of California, San Diego Medical Center Pediatric Neurology Pharmacist Rady's Children's Hospital, San Diego Assistant Clinical Professor University of California, San Diego School of Pharmacy University of California, San Francisco School of Pharmacy San Diego, California • Dr Tallian reports serving as a consultant for the San Diego Regional Center for Developmentally Delayed and California Institute of Mental Health.
John Watkins, RPh, MPH Director of Pharmacy Formulary Development Premera Blue Cross Mountlake Terrace, Washington • Dr Watkins reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Notice: In accordance with the ACPE Criteria for Quality, the audience is advised that articles in this continuing pharmaceutical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.
Dr Ryan–interferon beta-1a, interferon beta-1b, and glatiramer acetate.
All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.
University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies. |